May 23

HiLIFE webinar / Viikki Monday Seminar: Hilal Lashuel

​Rethinking Protein Aggregation in Neurodegenerative Diseases: From Concepts to Experimental Models and Therapies

Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. In 2001, he moved to Harvard Medical School and the Brigham and Women’s Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. In 2005, Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne (EPFL) as a tenure-track assistant professor in neurosciences, where he currently is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. 


Dr. Lashuel is an expert in biochemistry of neurodegeneration-related aggregation prone proteins, including alpha-synuclein, tau, huntingtin. He has more than 120 peer-review publications in high-quality peer-review journals.  He holds three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases. Dr. Lashuel is the recipient of Human Science Frontiers young investigator research award, the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013), Young Global Leader by the World Economic Forum (2012), the Michael J. Fox Foundation Parkinson’s disease Grand Challenge Award, Kuwait Prize in fundamental Sciences (Biological Sciences, 2018), Takreem Foundation Scientific and Technological Achievements Award (2019),  and H. Martin Friedman Distinguished Lecture (2020). In addition, Hilal Lashuel is the founder of ND BioSciences, a biotechnology startup established in 2019 developing technologies and services for the development of early diagnostics and therapies for neurodegenerative diseases, such as Parkinson’s and Alzheimer’s diseases. 


Lashuel research group 



Welcome to this exciting seminar!  

Safak Er 

NOTE: For PhD (or Master’s) students, there are few spaces available for student lunch with Dr Lashuel at Viikki. Please email if you want to join! 


Selected publications: 

Riguet, N., Mahul-Mellier, AL., Maharjan, N. et al (2021).. Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties. Nat Commun 12, 6579.  


Lashuel, H. A. (2021). Rethinking protein aggregation and drug discovery in neurodegenerative diseases. Current Opinion in Chemical Biology 64: 67-75. 

Mahul-Mellier, A.-L., Burtscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., Leleu, M., Knott, G. W., & Lashuel, H. A. (2020). The process of Lewy Body Formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proceedings of the National Academy of Sciences, 117(9), 4971–4982. 



University of Helsinki students please note: If you wish to obtain credits (DPBM, ILS) from this webinar series, please rename yourself in Zoom with first name + last name (do not use nickname/user ID/student number/just first name). 

Start time: 23/05/2022 13:00
End time: 23/05/2022 14:00
Duration: 1 hour
Location: Biocenter 2, Lecture Hall 1041, Viikinkaari 5
Type: Webinar
Organization: Helsinki Institute of Life Science HiLIFE
Contact person:
May 25

CancerBio Summer School&Cancer IO Sebinar: Douglas Hanahan

​Hallmarks of Caner - New Dimensions
Douglas Hanahan, born in Seattle, Washington, USA, received a bachelor’s degree in Physics from MIT (1976), and a Ph.D. in Biophysics from Harvard (1983). He worked at Cold Spring Harbor Laboratory in New York (1978-88) initially as a graduate student and then as a group leader. From 1988-2010 he was on the faculty of the Department of Biochemistry & Biophysics at UCSF in San Francisco. Hanahan joined the Lausanne Branch of the Ludwig Institute for Cancer Research as a Distinguished Scholar in January 2020. In addition, Hanahan is currently Professor and Director of the Swiss Institute for Experimental Cancer Research within the School of Life Sciences at EPFL, the Swiss Federal Institute of Technology Lausanne and Co-director of the new multi-institutional Swiss Cancer Center Leman. He has been elected to the American Academy of Arts & Sciences (2007), the US Institute of Medicine (2008), the US National Academy of Science (2009), and EMBO (2010). Hanahan has also received an honorary degree from the University of Dundee in the UK (2011) and the Lifetime Achievement Award from the AACR (2014). 
The Hanahan laboratory’s research program is structured around the use of genetically engineered mouse models (GEMMs) of multistep de novo tumorigenesis to investigate the hallmarks of cancer—the many distinct capabilities acquired by tumors and their constituent cells that are essential to the establishment and progression of cancers. The strategic plan is to elucidate the functional and phenotypic manifestations, molecular and cellular mechanisms, and regulation of hallmark capabilities—and to translate that knowledge into clinical applications, diagnostics and therapies. Currently Hanahan group investigates several organ-specific cancers, including ductal and neuroendocrine pancreatic cancers, cervical cancer, melanoma, metastatic breast cancer and glioblastoma. The group also have a robust program exploring the multiple mechanisms of immune evasion employed by tumors and strategies to disable such defenses to boost immunotherapy and broaden its applicability.

Selected publications 


D. Hanahan. Hallmarks of Cancer: New Dimensions. Cancer Discovery. 2022-01-01. DOI : 10.1158/2159-8290.CD-21-1059. 

S. SaghafiniaK. HomicskoA. Di DomenicoS. WullschlegerA. Perren, et al., D. Hanahan. Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression. Cancer Discovery. 2021-10-01. DOI : 10.1158/2159-8290.CD-20-1637. 

Q. ZengI. P. MichaelP. ZhangS. SaghafiniaG. Knott, et al., D. Hanahan. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 2019-09-26. DOI : 10.1038/s41586-019-1576-6. 

J. HuelskenD. Hanahan. A Subset of Cancer-Associated Fibroblasts Determines Therapy Resistance. Cell. 2018. DOI : 10.1016/j.cell.2018.01.028. 

S. SaghafiniaM. MinaN. RiggiD. HanahanG. CirielloPan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. Cell Reports. 2018-10-23. DOI : 10.1016/j.celrep.2018.09.082. 

K. ShchorsA. MassarasD. HanahanDual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit. Cancer Cell. 2015. DOI : 10.1016/j.ccell.2015.08.012. 

A. SadanandamC. A. LyssiotisK. HomicskoE. A. CollissonW. J. Gibb, et al., D. Hanahan. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine. 2013. DOI : 10.1038/nm.3175. 

L. LiD. Hanahan. Hijacking the Neuronal NMDAR Signaling Circuit to Promote Tumor Growth and Invasion. Cell. 2013. DOI : 10.1016/j.cell.2013.02.051. 

D. HanahanR. A. WeinbergHallmarks of Cancer: The Next Generation. Cell. 2011. DOI : 10.1016/j.cell.2011.02.013. 



Find out more information on Professor Hanahan's research and recent publications: 

Start time: 25/05/2022 13:00
End time: 25/05/2022 14:00
Duration: 1 hour
Location: remotely
Type: Seminar
Organization: CancerBio Summer School
Contact person:
May 25

Docentship lecture: Takashi Namba

"Adult neurogenesis in the human hippocampus: Death of a dogma or not?”


Length is 30min, after which there is discussion, and then the audience will evaluate the lecture. 

Start time: 25/05/2022 14:00
End time: 25/05/2022 15:00
Location: Biomeiducm 1, meeting room 3
Type: Docententship lecture
Organization: UH, Faculty of Medicine
Contact person:
June 08

Faculty of Medicine Honorary Doctors' Symposium

The Faculty of Medicine warmly invites everyone to the Honorary Doctors' Symposium on Wednesday 8.6.2022 in Biomedicum 1, Lecture Hall 1!


The symposium is organized as a part of the XV Conferment of the Faculty and features all the 10 honorary doctors participating in the festivities. For a detailed programme and a presentation of the international speakers, all of whom are experts in their respective fields, please see the attached programme.


The Symposium can be included in the theoretical studies of most fields of specialty.

Start time: 08/06/2022 09:00
End time: 08/06/2022 16:30
Duration: 7 hours 30 minutes
Location: Biomedicum1, lecture hall 1, Haartmaninkatu 8, 00290 Helsinki
Type: Symposium
Organization: UH, Faculty of Medicine
Contact person:
September 28

FiCAN Seminar

Juha Klefström, FICAN Research Professor University of Helsinki Organized by FICAN South
Start time: 28/09/2022 15:00
End time: 28/09/2022 16:00
Type: Seminar
Organization: Finnish Cancer Center (FICAN)
Contact person: